Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy of S 33138 versus risperidone in schizophrenia
2005-000016-27Phase 2Completed
- Sponsor
- Servier
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of S 33138 in schizophrenia (2 arms), sponsored by Servier. Primary endpoint: Clinical and biological safety of S 33138 after 8 weeks. Started Apr 2005; status: completed.
02
Drugs
S 33138
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2005-000016-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000016-27.